EMCURE PHARMA Q2 FY27 ; CONS NET PROFIT UP 29% AT ₹325 CR (YOY), UP 11% (QOQ)

REVENUE UP 24% AT ₹2,820 CR (YOY), UP 9% (QOQ) EBITDA UP 24% AT ₹588 CR (YOY), UP 10% (QOQ) MARGINS AT 20.8% VS 20.9% (YOY), 20.6% (QOQ)

EMCURE PHARMACEUTICALS L